Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 79.4 EUR 1.15% Market Closed
Market Cap: 1.4B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Pharma Mar SA
Intangible Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pharma Mar SA
Intangible Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Intangible Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pharma Mar SA
MAD:PHM
Intangible Assets
€1.2m
CAGR 3-Years
-28%
CAGR 5-Years
-21%
CAGR 10-Years
-26%
Grifols SA
MAD:GRF
Intangible Assets
€2.8B
CAGR 3-Years
22%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Intangible Assets
€89.9m
CAGR 3-Years
22%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Intangible Assets
€4.7m
CAGR 3-Years
-9%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
No Stocks Found

Pharma Mar SA
Glance View

Market Cap
1.4B EUR
Industry
Biotechnology

Nestled in the vibrant biotech landscape of Spain, Pharma Mar SA emerges as a pioneer, weaving the wonders of the sea into groundbreaking medical therapies. Born from the vision of harnessing marine biodiversity, the company delves into the vast oceanic expanse, unearthing bioactive compounds with potential therapeutic uses. This oceanic pursuit forms the backbone of its innovative approach, focusing on oncological drugs derived from the depths of the sea. Their portfolio showcases significant breakthroughs, with products like Yondelis, originally discovered in a sea squirt, reflecting their unique niche in the drug development pipeline. By advancing these marine-based molecules through intensive clinical research, Pharma Mar translates the ocean's secrets into lifesaving treatments, underscoring its hallmark presence in oncology. The company ingeniously monetizes this frontier exploration by orchestrating a business model encompassing rigorous R&D, strategic partnerships, and licensing agreements. Pharma Mar invests heavily in its research, channeling substantial resources into both preclinical and clinical trials to elevate these marine compounds into market-ready drugs. Partnering with global pharmaceutical heavyweights enables them to extend their market reach while sharing development costs and multiplying revenue streams through royalties and milestone payments. Furthermore, licensing their findings expands their financial foothold, allowing them to reap returns on their intellectual exploits without the burden of full-scale commercialization. Pharma Mar’s adept navigation of the pharmaceutical seas has thus firmly anchored its place within the global biotech arena.

PHM Intrinsic Value
89.32 EUR
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Pharma Mar SA's Intangible Assets?
Intangible Assets
1.2m EUR

Based on the financial report for Sep 30, 2024, Pharma Mar SA's Intangible Assets amounts to 1.2m EUR.

What is Pharma Mar SA's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
-26%

Over the last year, the Intangible Assets growth was -38%. The average annual Intangible Assets growth rates for Pharma Mar SA have been -28% over the past three years , -21% over the past five years , and -26% over the past ten years .

Back to Top